Benzinga | Sep 2, 2021 09:37AM EDT

BeiGene's Brukinsa Scores FDA Approval For Rare Blood Cancer Indication

* The FDA has approved BeiGene Ltd (NASDAQ:BGNE) Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenstr?m's macroglobulinemia (WM).

* Brukinsa WM approval is the second therapy approved specifically for the treatment of this rare type of lymphoma.

* The approval is primarily based on results from Phase 3 ASPEN trial.

* The very good partial response (VGPR) rate was 28% with Brukinsa, compared to 19% with ibrutinib.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: BGNE stock is up 0.35% at $328.39 during the market session on the last check Thursday.